Mathematical modeling of drug delivery from torus-shaped single-layer devices

Journal of Controlled Release

Volumn 149, Issue 3, 2011, Pages 258-263

  Helbling, Ignacio M ^a   Luna, Julio A ^a   Cabrera, María I ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Dispersed drug; Mathematical modeling; Moving front; Pseudo steady state approximation; Vaginal ring

Indexed keywords

DISPERSED DRUG; MATHEMATICAL MODELING; MOVING FRONT; PSEUDO-STEADY STATE APPROXIMATIONS; VAGINAL RING;

DRUG DELIVERY;

COMPUTER SIMULATION;

DISPERSANT; POLYMER;

ARTICLE; COMPARATIVE STUDY; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; MATHEMATICAL MODEL; PRIORITY JOURNAL; RELIABILITY; SIMULATION; SOLUTE; STEADY STATE;

COMPUTER SIMULATION; CONTRACEPTIVE DEVICES, FEMALE; DIFFUSION; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS;

EID: 79951933683     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.10.018     Document Type: Article

References (57)

1. E. Cicinelli, Intravaginal oestrogen and progestin administration: advantages and disadvantages, Best Pract. Res. Clin. Obstet. Gynaecol. 22 (2008) 391-405. (Pubitemid 351292331)
2. A. Hussain, F. Ahsan, The vagina as a route for systemic drug delivery, J. Control. Release 103 (2005) 301-313. (Pubitemid 40342532)
3. K. Vermani, S. Garg, The scope and potential of vaginal drug delivery, PSTT 3 (2000) 359-364.
4. N.J. Alexander, E. Baker, M. Kaptein, U. Karck, L. Miller, E. Zampaglione, Why consider vaginal drug administration? Fertil. Steril. 82 (2004) 1-12.
5. A.P. Sam, Controlled release contraceptive devices: a status report, J. Control. Release 22 (1992) 35-46.
6. J. Yoo, C.H. Lee, Drug delivery systems for hormone therapy, J. Control. Release 112 (2006) 1-14.
7. R. Sitruk-Ware, Contraception: an international perspective, Contraception 73 (2006) 215-222. (Pubitemid 43202169)
8. R.K. Malcolm, S. McCullagh, A.D. Woolfson, M. Catney, P. Tallon, A dynamic mechanical method for determining the silicone elastomer solubility of drug and pharmaceutical excipients in silicone intravaginal drug delivery rings, Biomaterials 23 (2002) 3589-3594. (Pubitemid 34626563)
9. R.K. Malcolm, A.D. Woolfson, J. Russell, C. Andrews, In vitro release of nonoxynol-9 from silicone matrix intravaginal rings, J. Control. Release 91 (2003) 355-364.
10. J.A. Russell, R.K. Malcolm, K. Campbell, A.D. Woolfson, High-performance liquid chromatographic determination of 17β-estradiol and 17β-estradiol-3-acetate solubilities and diffusion coefficients in silicone elastomeric intravaginal rings, J. Chromatogr. B 744 (2000) 157-163. (Pubitemid 30412061)
11. A.D. Woolfson, R.K. Malcolm, R.J. Gallagher, Design of a silicone reservoir intravaginal ring for the delivery of oxybutynin, J. Control. Release 91 (2003) 465-476. (Pubitemid 36976773)
12. A.D. Woolfson, G.R.E. Elliott, C.A. Gilligan, C.M. Passmore, Design of an intravaginal ring for the controlled delivery of 17β-estradiol as its 3-acetate ester, J. Control. Release 61 (1999) 319-328. (Pubitemid 29413026)
13. F.G. Burton, W.E. Skiens, N.R. Gordon, J.T. Veal, D.R. Kalkwarf, G.W. Duncan, Fabrication and testing of vaginal contraceptive devices designed for release of prespecified dose levels of steroids, Contraception 17 (1978) 221-230. (Pubitemid 8299765)
14. T.M. Jackanicz, Levonorgestrel and estradiol release from an improved contraceptive vaginal ring, Contraception 24 (1981) 323-339. (Pubitemid 12239506)
15. D.R. Kalkwarf, M.R. Sikov, L. Smith, R. Gordon, Release of progesterone from polyethylene devices in vitro and in experimental animals, Contraception 6 (1972) 423-431.
16. S.A. Matlin, A. Belenguer, P.E. Hall, Progesterone-releasing vaginal rings for use in postpartum contraception. I. In vitro release rates of progesterone from coreloaded rings, Contraception 45 (1992) 329-341.
17. Y.W. Chien, H.J. Lambert, D.E. Grant, Controlled drug release from polymeric devices. I. Technique for rapid in vitro release studies, J. Pharm. Sci. 63 (1974) 365-369.
18. K. Malcolm, D. Woolfson, J. Russell, P. Tallon, L. McAuley, D. Craig, Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings, J. Control. Release 90 (2003) 217-225. (Pubitemid 36694965)
19. J.A.H. Van Laarhoven, M.A.B. Kruft, H. Vromans, In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring, Int. J. Pharm. 232 (2002) 163-173.
20. F.J.M.E. Roumen, Review of the combined contraceptive vaginal ring, NuvaRing®, Ther. Clin. Risk Manage. 4 (2008) 441-451.
21. T.M.T. Mulders, T.O.M. Dieben, Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition, Fertil. Steril. 75 (2001) 865-870.
22. M. Tuppurainen, R. Klimscheffskij, M. Venhola, T.O.M. Dieben, The combined contraceptive vaginal ring (NuvaRing®) and lipid metabolism: a comparative study, Contraception 69 (2004) 389-394. (Pubitemid 38510329)
23. A. Novak, C. de la Loge, L. Abetz, E.A. Van der Meulen, The combined contraceptive vaginal ring, NuvaRing®: an international study of user acceptability, Contraception 67 (2003) 187-194.
24. M.W. Van den Heuvel, A.J.M. Van Bragt, A.K.M. Alnabawy, M.C.J. Kaptein, Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive, Contraception 72 (2005) 168-174. (Pubitemid 41133355)
25. E.D.B. Johansson, R. Sitruk-Ware, New delivery systems in contraception: vaginal rings, Am. J. Obstet. Gynecol. 190 (2004) S54-S59. (Pubitemid 38561494)
26. S.A. Ballagh, Vaginal ring hormone delivery systems in contraception and menopause, Clin. Obstet. Gynecol. 44 (2001) 106-113. (Pubitemid 32156087)
27. F.J.M.E. Roumen, D. Apter, T.M.T. Mulders, T.O.M. Dieben, Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol, Hum. Reprod. 16 (2001) 469-475. (Pubitemid 32218795)
28. T.O.M. Dieben, F.J.M.E. Roumen, D. Apter, Efficacy, cycle control and user acceptability of a novel combined contraceptive vaginal ring, Obstet. Gynecol. 100 (2002) 585-593. (Pubitemid 35246150)
29. C. Kim, Controlled release from triple layer, donut-shaped tablets with enteric polymers, AAPS Pharm. Sci. Tech. 6 (2005) E429-E436.
30. L. Wu, C.S. Brazel, Mathematical model to predict drug release, including the early-time burst effect, from swellable homogeneous hydrogels, Ind. Eng. Chem. Res. 47 (2008) 1518-1526.
31. X. Huang, C.S. Brazel, On the importance and mechanisms of burst release in matrix-controlled drug delivery systems, J. Control. Release 73 (2001) 121-136. (Pubitemid 32539245)
32. F. Siepmann, S. Herrmann, G. Winter, J. Siepmann, A novel mathematical model quantifying drug release fromlipid implants, J. Control. Release 128 (2008) 233-240.
33. D.Y. Arifin, L.Y. Lee, C.H. Wang, Mathematical modeling and simulation of drug release from microspheres: implications to drug delivery systems, Adv. Drug Deliv. Rev. 58 (2006) 1274-1325.
34. G. Frenning, Theoretical analysis of the release of slowly dissolving drug from spherical matrix systems, J. Control. Release 95 (2004) 109-117. (Pubitemid 38167685)
35. T. Higuchi, Rate of release of medicaments from ointment bases containing drug in suspension, J. Pharm. Sci. 50 (1961) 874-875.
36. T. Higuchi, Mechanism of sustained-action medication, J. Pharm. Sci. 52 (1963) 1145-1149.
37. T.J. Roseman, W.I. Higuchi, Release of medroxyprogesterone acetate from a silicone polymer, J. Pharm. Sci. 59 (1970) 353-357.
38. K. Tojo, Intrinsic release rate from matrix-type drug delivery systems, J. Pharm. Sci. 74 (1985) 685-687.
39. Y. Zhou, X.Y. Wu, Theoretical analyses of dispersed-drug release from planar matrices with a boundary layer in a finite medium, J. Control. Release 84 (2002) 1-13. (Pubitemid 35223409)
40. I.M. Helbling, J.C.D. Ibarra, J.A. Luna, M.I. Cabrera, R.J.A. Grau, Modeling of drug delivery from erodible and non-erodible laminated planar devices into a finite external medium, J. Memb. Sci. 350 (2010) 10-18.
41. K.M. Marentette, A.E. Grosser, Modeling of the kinetics of drug release from a binary system, J. Pharm. Sci. 81 (1992) 318-320.
42. T.J. Roseman, Release of steroids froma silicone polymer, J. Pharm. Sci. 61 (1972) 46-50.
43. Y. Zhou, X.Y. Wu, Modeling and analysis of dispersed-drug release into a finite medium from sphere ensembles with a boundary layer, J. Control. Release 90 (2003) 23-36. (Pubitemid 36588876)
44. J. Siepmann, F. Siepmann, Mathematical modeling of drug delivery, Int. J. Pharm. 364 (2008) 328-343.
45. J. Siepmann, A. Göpferich, Mathematical modeling of bioerodible, polymeric drug delivery systems, Adv. Drug Deliv. Rev. 48 (2001) 229-247.
46. P. Costa, J.M. Sousa Lobo, Evaluation ofmathematicalmodels describing dug release from estradiol transdermal systems, Drug Dev. Ind. Pharm. 29 (2003) 89-97. (Pubitemid 36205885)
47. M.N. Özisik, Heat Conduction, John Wiley & Sons Inc, New York, 1980.
48. J. Crank, The Mathematics of Diffusion, second ed.Clarendon Press, Oxford, 1975.
49. A. Fick, Ueber diffusion, Ann. Phys. 170 (1855) 59-86.
50. Y.W. Chien, Fundamentals of controlled-release drug administration, in: Novel Drug Delivery System (Ed.), J. Swarbrick, Marcel Dekker Inc., New York and Basel, 1982, pp. 465-574.
51. V. Pillay, R. Fassihi, Evaluation and comparison of dissolution data derived from different modified release dosage forms: an alternative method, J. Control. Release 55 (1998) 45-55. (Pubitemid 28477563)
52. P. Costa, J.M. Sousa Lobo, Modeling and comparison of dissolution profiles, Eur. J. Pharm. Sci. 13 (2001) 123-133. (Pubitemid 32288781)
53. J.W. Moore, H.H. Flanner, Mathematical comparison of dissolution profiles, Pharm. Tech. 20 (1996) 64-74.
54. Food and Drug Administration. Guidance for industry: immediate release solid oral dosage forms. Scale-up and postapproval changes: chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo BE documentation. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 1995.
55. Committee for Proprietary Medicinal Products. Note for guidance on quality of modified release products: A: oral dosage forms, B: transdermal dosage forms. Section I (Quality). CPMP/QWP/604/96. London, England: Committee for Proprietary Medicinal Products; 1999.
56. I. Sivin, D.R. Mishell, F. Alvarez, V. Brache, K. Elomaa, P. Lähteenmäki, R. Massai, P. Miranda, H. Croxatto, C. Dean, M. Small, H. Nash, T.M. Jackanicz, Contraceptive vaginal rings releasing Nestorone® and ethinylestradiol: a 1-year dose-finding trial, Contraception 71 (2005) 122-129. (Pubitemid 40222065)
57. T. Maruo, D.R. Mishell, A. Ben-Chetrit, D. Hochner-Celnikier, A.L. Hamada, H.A. Nash, Vaginal rings delivering progesterone and estradiol may be a new method of hormone replacement therapy, Fertil. Steril. 78 (2002) 1010-1016.